Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
2018-004840-51Phase 2Terminated
- Sponsor
- CervoMed
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neflamapimod in Huntington disease (HD) (2 arms), sponsored by CervoMed. Primary endpoint: Latency during the learning phase of virtual Morris Water Maze. Started Mar 2019; status: terminated.
02
Drugs
neflamapimod
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2018-004840-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004840-51.